Drug Approval | May 18, 2025
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India
EBITDA before special items decreases to €4.08 billion (7.4%)
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
Scores highest PAT of Rs. 118 crore in FY25
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Subscribe To Our Newsletter & Stay Updated
